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Objective: Diabetes causes changes in the salivary glands and in the composition of saliva, as
well as symptoms such as dry mouth and hyposalivation. Therefore, this study aimed at
investigating changes in salivary secretion and composition, in response to parasympa-
thetic stimuli, in diabetic rats induced with streptozotocin.
Design: Diabetes was induced by a single intraperitoneal injection of streptozotocin. Thirty
days after diabetes induction, the animals were anaesthetized and salivation was stimu-
lated by an intraperitoneal injection of Pilocarpine (0.6 mg/kg body weight) dissolved in
distilled water. Saliva was collected for 40 min and immediately stored at 80 8C until
analysis. The salivary flow rate, amount of total protein, amylase and peroxidase activities,
and free and total sialic acid contents were measured.
Results: Salivary flow rate was reduced in the diabetic group ( p < 0.05). Moreover, increases
in total protein amount and in amylase and peroxidase activities were observed in diabetic
animals. No difference was observed for free sialic acid content between groups. On the
other hand, a significantly decrease in the total sialic acid content was observed in the
diabetic group ( p < 0.05).
Conclusions: Our findings suggest that a decrease in sialic acid in the saliva of diabetic
animals can be related to xerostomia reported by diabetic patients. However, further clinical
trials are needed to verify if the decrease in sialic acid also occurs in human saliva.
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According to new estimates from World Health Organization
(WHO), 346 million people worldwide have diabetes. Altera-
tions in salivary gland composition and salivary gland
hypofunction have been associated with elevated fasting
blood glucose concentrations (hyperglycaemia) and neuropa-
thy.1–3 Dry mouth (xerostomia) associated or not with
hyposalivation is a frequent clinical complaint among patients
with type 1 and type 2 diabetes.4 It has been estimated that
more than half of all individuals with diabetes experience oral* Corresponding author at: Departamento de Materiais Denta´rios, Fa
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E-mail address: fnn@usp.br (F.N. Nogueira).
0003–9969 # 2012 Elsevier Ltd. 
doi:10.1016/j.archoralbio.2012.02.016
Open access under the Elsevier OA license.dryness and studies involving patients with diabetes reported
decreased salivary flow rate.1,6,7 Increase in dental caries,
gingivitis, periodontitis, alveolar bone loss, tooth-loss, soft
tissue lesions have also been reported in diabetes.8–10
Saliva plays an important role in oral health due to its
numerous functions and compounds. One of the major
functions of saliva is lubrication of the oral mucosa.11 Mucin,
a human salivary glycoprotein, is very important for lubrica-
tion. This glycoprotein is soluble, hydrophilic and retains
significant amounts of water, consequently preventing muco-
sal dehydration.12 Sialic acid is an important constituent of
mucin and can be found free and bound to protein, although itculdade de Odontologia Av. Prof. Lineu Prestes, 2227 – Cidade
x: +55 11 30917840.
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oligosaccharide chains (like mucins).
Biochemical alterations in salivary glands of diabetic
animals have been reported in rats subjected to streptozotocin
or alloxan injections.13–16 Alterations in salivary composition
and salivary flow have already been observed in clinical
trials.1,6 However, there are few studies involving changes in
salivary composition of diabetic rats.13,14 Moreover, to the best
of our knowledge, no study reported changes in the amount of
salivary sialic acid in diabetic rats.
Pilocarpine is an alkaloid used to stimulate saliva flow,
which acts as a parasympathetic agonist in cholinergic
muscarinic receptors present in the salivary glands.17 Some
studies show that the maximum response to stimulation with
this agonist in salivary flow is depressed in diabetic animals
and can be a consequence of a dysfunction of muscarinic
receptors, causing hyposalivation and xerostomia.15,16
Therefore, this study aimed at investigating changes in
salivary secretion and composition in response to parasym-
pathetic stimuli in diabetic rats induced with streptozotocin.
2. Materials and methods
2.1. Animals
The Protocol of this study was approved by the Bioethics
Committee of Animals, from the Institute of Biomedical
Sciences of the University of Sa˜o Paulo. Sixteen male Wistar
rats (200 g) were randomly divided into two groups: control (C)
and diabetic (D), which were maintained in individual cages
with free access to food and water in a 12 h light/12 h dark
cycle during the experimental period.
2.2. Diabetes induction
Diabetes was induced in overnight-fasted rats by a single
intraperitoneal injection of streptozotocin (STZ) (60 mg/kg
body weight) dissolved in 0.1 M citrate sodium buffer, pH 4.5.
The control animals received only the citrate buffer. Develop-
ment of diabetes was confirmed by blood glucose analysis of
overnight fasted animals, using the blood glucose meter Accu
Chek Advantage (Roche-Diagnostics1, Mannheim, Germany),
72 h after the STZ injection. Rats with blood glucose level
above 14 mM (250 mg/100 ml) were considered diabetic.
2.3. Stimulation of salivation
Thirty days after diabetes induction, the overnight-fasted
animals were anaesthetized with an intraperitoneal injection
of Ketamine (Dopalen, Vetbrands) (1 ml/kg) and Xylazine
Chloride (Anasedan, Vetbrands) (0.1 ml/kg). Under the effect of
anaesthesia, the salivation was stimulated with an intraperi-
toneal injection of Pilocarpine (0.6 mg/kg body weight)
dissolved in distilled water. Saliva was collected using pre-
weighted small cotton balls inserted into the animals mouth
for 40 min. The salivary flow rate was determined by dividing
the difference in weight of the cotton ball before and after
collection by the time span. The saliva was then immediately
stored at 80 8C until analysis.2.4. Analysis
Amylase activity was determined by the method described by
Fisher and Stein.18 Saliva samples were incubated with 1%
starch solution in 20 mM phosphate buffer, pH 7.0, and
maltose solution (1 mg/ml of distilled water), for 5 min at
37 8C. The reaction was halted by adding an alkaline solution
of dinitrosalicylic acid, and the mixture was then diluted and
maintained in boiling water for 5 min. The colour intensity
was measured at 530 nm in a Beckman DU-68 spectropho-
tometer (Beckman, Fullerton, CA). Data was expressed in mg
of maltose per mg of salivary protein.
The activity of peroxidase was determined using a Chandra’s
method19 modified by Anderson.20 The interference of pseu-
doperoxidase activity was eliminated by carrying out duplicate
assays in the presence of 10 mM 3-amino-1,2-triazole, an
inhibitor of peroxidase activity. Peroxidase activity was
measured in a medium containing 8 mM phosphate buffer,
pH 6.0, 1 mM O-dianisidine and saliva samples. The reaction
was started by adding H2O2 to a final concentration of 0.02 mM
and maintained for 5 min. The concentration of peroxidase in
the samples was expressed in mg/mg of protein and based on a
standard curve with different concentrations of lactoperox-
idase. The absorbance was measured at 460 nm in a Beckman
DU-68 spectrophotometer (Beckman, Fullerton, CA).
The sialic acid levels (free and total) were determined by
thiobarbituric acid assay, using N-acetyl-neuraminic as a
standard.21,22 Total sialic acid was determined after hydrolysis
of the sample in 0.1 N sulphuric acid at 80 8C for 1 h. After
hydrolysis, the samples were treated with periodate reagent
(25 mM periodic acid in 0.125 N sulphuric acid) and incubated
at 37 8C for 30 min. The reaction was stopped by the addition of
sodium arsenite (2% sodium arsenite in 0.22 M hydrochloric
acid). After disappearance of the iodine colour, 0.1 M thio-
barbituric acid solution (pH 9.0) was added; the solution was
heated in boiling water, and then cooled to room temperature.
Dimethylsulphoxide was added, and the intensity of devel-
oped colour was measured at 549 nm in a Beckman DU-68
spectrophotometer (Beckman, Fullerton, CA). The concentra-
tion of free sialic acid in the saliva samples was determined
following the same procedure as described above, with the
exception of hydrolysis. The amount of bound sialic acid was
calculated as the difference between total and free sialic acid.
Data was expressed in nM/mg protein.
The protein concentration was measured using Folin’s
phenol reagent, as described elsewhere; bovine serum albumin
was used as a standard. The Beckman DU-68 spectrophotome-
ter (Beckman, Fullerton, CA) readings were taken at 660 nm.23
2.5. Statistical analysis
The statistical significance was calculated using Student’s t
test, and the level of significance was set at 5%. Data are
presented as mean  standard deviation (SD).
3. Results
The body weight of the control group increased by 28%,
whereas the body weight of the diabetic animals decreased by
Table 1 – Characteristics of stimulated saliva from control
and diabetic rats (mean W SD).
Control (n = 8) Diabetic (n = 8)
Flow rate (ml/min) 35.9  4.42 8.81  4.22*
Protein (mg/ml) 1.33  0.41 1.90  0.48*
Peroxidase (mg/mg protein) 0.00133  0.00085 0.26  0.217*
Amylase (mg of maltose/mg
protein)
124.6  54.9 265.4  108.6*
* Difference between the control and diabetic values of each
parameter ( p < 0.05).
Table 2 – Values of total, free and bound sialic acid of
control and diabetic rats (mean W SD).
Sialic acid (mM/mg protein)
Control (n = 8) Diabetic (n = 8)
Total 0.0218  0.005 0.0113  0.004*
Free 0.0025  0.0013 0.0029  0.0014
Bound 0.0192  0.0046 0.0084  0.0046*
* Difference between the control and diabetic values ( p < 0.05).
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had blood glucose levels higher than 250 mg/100 ml and these
levels did not change until the euthanasia day.
The salivary flow rate was reduced by 75% in the diabetic
group ( p < 0.05). Concerning the salivary composition,
increases in the total protein (43%), as well as in amylase
(114%) and peroxidase (2000%) activities were observed in
diabetic animals (Table 1).
No difference was observed in free sialic acid content
between both groups, but a significant decrease (56%) in the
total sialic acid content was observed in the diabetic group
( p < 0.05) (Table 2).
4. Discussion
The aim of this study was to investigate changes in salivary
secretion and composition in response to parasympathetic
stimuli. In this study we found reduction in salivary flow rate.
In order to relate and understand this decrease, two enzymes,
which are known as markers of parotid salivary gland
function, amylase and peroxidase, were analysed.24 The
concentration of both enzymes was high in the saliva of
diabetic rats. These results indicate that, although salivary
flow is reduced in diabetic rats, the secretory process in this
salivary gland is still functioning. Therefore, we decided to
measure the concentration of sialic acid, a submandibular
gland function marker,25 in the saliva of rats and found lower
concentrations of sialic acid in the saliva of diabetic animals,
when compared to the control group.
Rats can be used as experimental models to study salivary
secretion in humans due to the similarities of their salivary
glands, mainly regarding the final secretory products and
ductal system. Salivary gland secretion is regulated by both
sympathetic (adrenergic) and parasympathetic (cholinergic)
neurotransmitters. Since salivation is decreased in rats at rest,
high concentrations of pilocarpine (higher than 1 mg/kg ofbody weight) are used to stimulate the production of saliva in
studies on salivary secretion.15,26,27
It is well established that the muscarinic receptors in
salivary glands of diabetic animals have lower susceptibility
than those of the control animals.13,15,28 However, by
comparing diabetic and control animals, this study aimed at
verifying if the changes in the muscarinic receptors also occur
in animals which were less stimulated to produce saliva.
Therefore, the lowest dose possible to stimulate salivary
secretion in diabetic rats was used.
Xerostomia, which is a common complaint among diabetic
patients, can be often associated with decreased salivary flow.
Some studies suggest that xerostomia is associated with
salivary gland damage, resulting in marked decrease in its
ability to synthesize, transport and/or secrete saliva.1,29,30
Reduction in the flow rate was observed in the diabetic
group, although the total protein concentration was increased.
Recent studies have demonstrated that changes in the
transport of water are related to a protein called sodium-
glucose transporter 1 (SGLT1), which not only transports
glucose, but also acts as a water channel31 in the parotid gland
of diabetic rats. Additionally, there is some evidence that this
co-transporter plays an important role, acting as a water
pump.32 Reduction in the level of AQP5 (aquaporine-5), a very
important water channel protein, was also reported in the
parotid gland of diabetic rats.33 This reduction leads to a
decrease in water flow during the formation of the primary
saliva and, associated with the increase in the expression of
SGLT1 in this saliva, may explain the decrease in the salivary
flow in the diabetic group.
Salivary peroxidase is an enzyme secreted by salivary
glands, which plays an important role in oral health due to its
antioxidant and antimicrobial properties.34,35 Salivary amy-
lase constitutes a significant proportion of saliva, since it
comprises approximately 50% of the proteins produced by
salivary glands.36 These proteins are secreted mainly by
parotid glands and used as function markers for these
glands.24 The increase in the amount of both enzymes in
saliva of diabetic rats suggests that the secretion of amylase
and peroxidase by the parotid gland is not impaired but the
secretion of water promoted by the parasympathetic stimuli is
compromised. Moreover, a recent study demonstrated an
increased antioxidant capacity of the parotid gland in diabetic
rats suggesting a lower susceptibility of this gland for
oxidative damages in the diabetic state.37
In the present study, diabetic rats showed a significant
drop in total sialic acid content, caused by a decrease in
bound sialic acid content, since the free sialic acid content
did not change significantly. The decrease of salivary sialic
acid level in diabetes may be due to changes in the activity of
the enzymes which participate in the synthesis of sialic
acid.38 The sialic acid is secreted mainly by submandibular
glands and this process is calmodulin-dependent.25 High
concentration of glycated calmodulin, less effective than the
non-glycated calmodulin, was demonstrated previously in
diabetic rats.39 The increase of the glycated calmodulin could
be responsible for the reduction of sialic acid secretion and
mucin concentration in the saliva of diabetic rats. Changes in
the concentration of sialic acid in mucin can be related to
oral dryness. When mucin-based saliva substitutes are
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decrease in oral dryness.40
Our findings suggest that a decrease in sialic acid in the
saliva of diabetic animals can be related to xerostomia
reported by diabetic patients. However, further clinical trials
are needed to verify if the decrease in sialic acid also occurs in
human saliva.
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